Cidara Therapeutics(NASDAQ) CDTX
This security has been delisted. This page is retained for historical reference.
| Metric | Price | Date |
|---|---|---|
| Last close | USD 221.38 | 2026-01-06 |
| Period | Price return | Price at period start | Period start date |
|---|---|---|---|
| 1 week | +0.26% | USD 220.80 | 2025-12-30 |
| 1 month | +0.46% | USD 220.36 | 2025-12-05 |
| 3 month | +124.73% | USD 98.51 | 2025-10-08 |
| Year to date | +0.22% | USD 220.89 | 2025-12-31 |
| 1 year | +725.74% | USD 26.81 | 2025-01-06 |
| 3 year | +1,244.79% | USD 16.46 | 2023-01-06 |
| 5 year | +375.06% | USD 46.60 | 2021-01-07 |
| Since inception | -30.82% | USD 320.00 | 2015-04-15 |
CDTX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowCDTX Financials
Key Financial Metrics (TTM)
Gross Margin
Operating Margin
Net Income Margin
Return on Equity
Return on Capital
Return on Assets
Earnings Yield
Dividend Yield
Payout Ratio
Stock Overview
Market Cap
Shares Outstanding
Volume
Avg. Volume
Financials (TTM)
Gross Profit
Operating Income
EBITDA
Operating Cash Flow
Capital Expenditure
Free Cash Flow
Cash & ST Invst.
Total Debt
Cidara Therapeutics Performance Analysis
| Fiscal year | Period end | Revenue | YoY growth |
|---|---|---|---|
| 2021 | 2021-12-31 | USD 49,572,000 | N/A |
| 2022 | 2022-12-31 | USD 64,448,000 | 30.0% |
| 2023 | 2023-12-31 | USD 23,283,000 | -63.9% |
| 2024 | 2024-12-31 | USD 1,275,000 | -94.5% |
| Fiscal quarter | Period end | QoQ growth |
|---|---|---|
| Q4 | 2024-12-31 | N/A |
| Q1 | 2025-03-31 | N/A |
| Q2 | 2025-06-30 | N/A |
| Q3 | 2025-09-30 | N/A |
| Fiscal year | Period end | Diluted EPS | YoY growth |
|---|---|---|---|
| 2021 | 2021-12-31 | USD -16.19 | N/A |
| 2022 | 2022-12-31 | USD -9.62 | -40.6% |
| 2023 | 2023-12-31 | USD -5.25 | -45.4% |
| 2024 | 2024-12-31 | USD -26.46 | 404.5% |
| Fiscal quarter | Period end | QoQ growth |
|---|---|---|
| Q4 | 2024-12-31 | -125.6% |
| Q1 | 2025-03-31 | 69.1% |
| Q2 | 2025-06-30 | 0.6% |
| Q3 | 2025-09-30 | -87.9% |
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
N/A
Gross Profit
-262.1%
Gross Margin
N/A
Market Cap
N/A
Market Cap/Employee
N/A
Employees
N/A
Net Income
-420.7%
EBITDA
-437.7%
Quarterly Fundamentals
Total Cash
+130.5%
Total Debt
-49.7%
Accounts Receivable
+9.5%
Inventory
N/A
Long Term Debt
-82.0%
Short Term Debt
-1.3%
Return on Assets
N/A
Return on Invested Capital
N/A
Free Cash Flow
-10.4%
Operating Cash Flow
-10.7%